Perbak Capital Partners’s Praxis Precision Medicines PRAX Stock Holding History

Perbak Capital Partners’s Portfolio PRAX Stock Details PRAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-799	Closed	-$257K	–	187
2026 Q1	$257K	Buy	+799	New	+$247K	0.06%	270

Other funds holding PRAX

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Perbak Capital Partners's PRAX Position: Q2 2026 in Review

Perbak Capital Partners sold out of Praxis Precision Medicines (PRAX) in Q2 2026, closing a stake of 799 shares — an estimated $257K sold.

Perbak Capital Partners first reported a position in PRAX in Q1 2026 and held it in 1 quarter. The position peaked at $257K in Q1 2026. 310 funds tracked by Wall St. Rank hold PRAX as of Q2 2026.

Perbak Capital Partners reported no remaining Praxis Precision Medicines position as of Q2 2026 after selling out during the quarter.
Perbak Capital Partners sold 799 Praxis Precision Medicines shares in Q2 2026, an estimated $257K.
Perbak Capital Partners first reported a position in Praxis Precision Medicines in Q1 2026 and held it in 1 quarter.
Perbak Capital Partners's Praxis Precision Medicines position peaked at $257K in Q1 2026.
310 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q2 2026.

Based on Perbak Capital Partners's 13F filing for Q2 2026.